Effect of chemosensitizers on minimum inhibitory concentrations of fluconazole in Candida albicans

Medical Principles and Practice

Volumn 17, Issue 2, 2008, Pages 117-121

  Bulatova, Nailya R ^a   Darwish, Rula M ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Candida albicans; Chemosensitizers; Fluconazole

Indexed keywords

CHLORPROMAZINE; CYCLOSPORIN; DESIPRAMINE; DILTIAZEM; FLUCONAZOLE; GEMFIBROZIL; LANSOPRAZOLE; NICARDIPINE; PROCHLORPERAZINE; PROMETHAZINE; QUINIDINE; QUININE; RESERPINE; TAMOXIFEN; THIORIDAZINE; TRIFLUOPERAZINE; VERAPAMIL;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CHEMOSENSITIZATION; DRUG EFFECT; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CELLS, CULTURED; CHLORPROMAZINE; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; NICARDIPINE; RESERPINE;

EID: 39749108876     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112964     Document Type: Article

References (25)

1. Georgiev VS: Membrane transporters and antifungal drug resistance. Curr Drug Targets 2000;1:261-284.
2. Mateus C, Crow SA Jr, Ahearn DG: Adherence of Candida albicans to silicone induces immediate enhanced tolerance to fluconazole. Antimicrob Agents Chemother 2004;48:3358-3366.
3. Sanglard D, Odds FC: Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002;2:73-85.
4. Fling ME, Kopf J, Tamarkin A, Gorman JA, Smith HA, Koltin Y: Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet 1991;227:318-329.
5. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J: Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995;39:2378-2386.
6. Calabrese D, Bille J, Sanglard D: A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology 2000;146: 2743-2754.
7. White TC, Holleman S, Dy F, Mirels LF, Stevens DA: Resistance mechanisms in clinical isolates of Candida albicans . Antimicrob Agents Chemother 2002;46:1704-1713.
8. Prasad R, De Wergifosse P, Goffeau A, Balzi E: Molecular cloning and characterization of a novel gene of Candida albicans, CDR1 conferring multiple resistance to drugs and antifungals. Curr Genet 1995;27:320-329.
9. Sanglard D, Ischer F, Monod M, Bille J: Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 1996;40:2300-2305.
10. Sanglard D, Ischer F, Monod M, Bille J: Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997;143:405-416.
11. Walsh TJ, Kasai M, Francesconi A, Landsman D, Chanock SJ: New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance. J Med Vet Mycol 1997;35:133-137.
12. Krishna R, Mayer LD: Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr Med Chem Anticancer Agents 2001;1:163-174.
13. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D: Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 2000;44: 2373-2381.
14. Bastert J, Schaller M, Korting HC, Evans EG: Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromized hosts. Int J Antimicrob Agents 2001;17:81-91.
15. Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005;5:30.
16. Schuetzer-Muehlbauer M, Willinger B, Egner R, Ecker G, Kuchler K: Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeasts. Int J Antimicrob Agents 2003;22:291-300.
17. Sugar AM, Liu X-P, Chen R-J: Effectiveness of quinolone antibiotics in modulating the effect of antifungal drugs. Antimicrob Agents Chemother 1997;41:2518-2521.
18. Lee MD, Galazzo JL, Staley AL, Lee JC, Warren MS, Fuernkranz H, et al: Microbial fermentation-derived inhibitors of efflux-pump-mediated drug resistance. Farmaco 2001;56:81-85.
19. Pina-Vaz C, Rodrigues AG, Costa-de-Oliveira S, Ricardo E, Mardh PA: Potent synergistic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry. J Antimicrob Chemother 2005;56:678-685.
20. Afeltra J, Verweij PE: Antifungal activity of nonantifungal drugs. Eur J Clin Microbiol Infect Dis 2003;22:397-407.
21. Niimi M, Wada S, Tanabe K Kaneko A, Takano Y, Umeyama T, et al: Functional analysis of fungal drug efflux transporters by heterologous expression in Saccharomyces cerevisae . Jpn J Infect Dis 2005;58:1-7.
22. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; ed 2, approved standard M27-A2. Wayne, NCCLS, 2002.
23. Hu XF, Martin TJ, Bell DR, de Luise M, Zalcberg JR: Combined use of cyclosporine A and verapamil in modulating multidrug resistance in human leukemia cells. Cancer Res 1990;50:2953-2957.
24. Hwang M, Ahn CH, Pine PS, Yin JJ, Hrycyna CA, Licht T, et al: Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells. Int J Cancer 1996;65:389-397.
25. van Schalkwyk DA, Walden JC, Smith PJ: Reversal of chloroquine resistance in Plasmodium falciparum using combinations of chemosensitizers. Antimicrob Agents Chemother 2001;45:3171-3174.